论文部分内容阅读
中华医学会与北京市结核病研究所于1978年联合召开关于异烟肼(INH)和氨硫脲(TB_1)治疗肺结核问题座谈会。国内部分地区已开始把INH-TB_1联合疗法作为大面积防治结核病的基本治疗方案之一。从抗结核作用看,TB_1仅具有抑制结核菌作用,但它半寿期长,平均血浓度可达最低抑菌浓度的10倍。其与INH并用,能延缓INH耐药性的产生。在试管内混合后两药有协同作用,可大大提高对结核菌的抑菌作用。与会各单位一致认为INH与TB_1联合应用是有肯定效果的,特别是在广泛开展农村结核病
The Chinese Medical Association and the Beijing Tuberculosis Institute held a joint symposium on the treatment of tuberculosis with isoniazid (INH) and thiosemicarbazide (TB_1) in 1978. In some parts of China, INH-TB_1 combination therapy has been started as one of the basic treatment programs for large-scale TB control. From the perspective of anti-TB effect, TB_1 only has the effect of inhibiting TB, but it has a long half-life and an average blood concentration of up to 10 times the minimum inhibitory concentration. Its use with INH, can delay INH drug resistance. After mixing in vitro with the two drugs have a synergistic effect, can greatly enhance the antimicrobial effect of TB. The participating units agreed that the joint application of INH and TB_1 has a positive effect, especially in the extensive rural tuberculosis